此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Veliparib、紫杉醇和卡铂治疗转移性或无法通过手术切除的实体瘤和肝肾功能障碍患者

2026年11月17日 更新者:National Cancer Institute (NCI)

ABT-888 联合卡铂和紫杉醇治疗肝肾功能不全和实体瘤患者的早期 1 期研究

This phase I trial studies the side effects and the best dose of veliparib when given together with paclitaxel and carboplatin in treating patients with solid tumors that are metastatic or cannot be removed by surgery and liver or kidney dysfunction. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving veliparib together with paclitaxel and carboplatin may kill more tumor cells.

研究概览

地位

主动,不招人

条件

干预/治疗

详细说明

PRIMARY OBJECTIVES:

I. To determine the pharmacokinetics and pharmacodynamics of ABT-888 (veliparib) in patients with varying degrees of renal or hepatic dysfunction.

II. To determine the maximum tolerated dose (MTD) of ABT-888 in combination with carboplatin and paclitaxel for patients with varying degrees of liver or kidney dysfunction.

III. To provide dosing recommendations for ABT-888 in combination with carboplatin and paclitaxel based on degree of hepatic and renal impairment.

SECONDARY OBJECTIVES:

I. To define the dose-limiting toxicity (DLT) and other toxicities associated with the use of this combination in patients with varying degrees of renal or hepatic dysfunction.

II. To evaluate the pharmacokinetic parameters of ABT-888, carboplatin, and paclitaxel when administered as a combination in patients with varying degrees of renal or hepatic dysfunction.

III. To evaluate the pharmacodynamic measurement of poly-ADP-ribosylated (PAR) and platinum adducts in tumor cells associated with the use of this combination in patients with varying degrees of renal or hepatic dysfunction.

OUTLINE: This is a dose-escalation study of veliparib.

Patients receive veliparib* orally (PO) twice daily (BID) on days 1-7 and paclitaxel intravenously (IV) over 3 hours and carboplatin IV over 30 minutes on day 3. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.

NOTE: * All patients receive a single dose of veliparib PO on day -6 before course 1 (except patients with very severe renal dysfunction who receive veliparib on day -5 or -6 to coincide with a dialysis day).

After completion of study treatment, patients are followed up for 4 weeks.

研究类型

介入性

注册 (实际的)

94

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • California
      • Duarte、California、美国、91010
        • City of Hope Comprehensive Cancer Center
      • Sacramento、California、美国、95817
        • University of California Davis Comprehensive Cancer Center
      • South Pasadena、California、美国、91030
        • City of Hope South Pasadena
    • Florida
      • Tampa、Florida、美国、33612
        • Moffitt Cancer Center
    • Georgia
      • Atlanta、Georgia、美国、30322
        • Emory University Hospital/Winship Cancer Institute
    • Maryland
      • Baltimore、Maryland、美国、21287
        • Johns Hopkins University/Sidney Kimmel Cancer Center
    • Massachusetts
      • Boston、Massachusetts、美国、02215
        • Dana-Farber Cancer Institute
    • Michigan
      • Detroit、Michigan、美国、48201
        • Wayne State University/Karmanos Cancer Institute
    • New Jersey
      • New Brunswick、New Jersey、美国、08903
        • Rutgers Cancer Institute of New Jersey
    • New York
      • New York、New York、美国、10065
        • Memorial Sloan Kettering Cancer Center
      • The Bronx、New York、美国、10467
        • Montefiore Medical Center - Moses Campus
      • The Bronx、New York、美国、10461
        • Montefiore Medical Center-Weiler Hospital
    • Ohio
      • Cleveland、Ohio、美国、44106
        • Case Western Reserve University
    • Pennsylvania
      • Hershey、Pennsylvania、美国、17033-0850
        • Penn State Milton S Hershey Medical Center
      • Pittsburgh、Pennsylvania、美国、15232
        • UPMC Hillman Cancer Center
    • Texas
      • Houston、Texas、美国、77030
        • UT MD Anderson Cancer Center
    • Wisconsin
      • Madison、Wisconsin、美国、53792
        • University of Wisconsin Carbone Cancer Center - University Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Patients must have histologically confirmed malignancy that is radiologically evaluable and metastatic or unresectable, for which standard curative or palliative measures do not exist or are no longer effective, and for which there is expectation of response to the combination of carboplatin/paclitaxel (i.e., lung, ovarian, breast, melanoma, head and neck, endometrial, urothelial, testicular, esophageal, carcinoma of unknown primary); for indications not listed, eligibility based on disease must be verified by the principal investigator before they are considered
  • Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
  • Life expectancy of greater than 12 weeks
  • Absolute neutrophil count >= 1,500/mcL
  • Platelets >= 100,000/mcL
  • Hemoglobin >= 8.0 g/dL
  • Patients with all degrees of renal dysfunction are allowed including patients on hemodialysis; patients with mild to severe hepatic dysfunction are allowed as defined below:
  • Total bilirubin =< 5 x upper limit of normal (ULN)
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 10 x ULN
  • For patients with a recently placed biliary stent, patients should have consistent results within a hepatic group from two laboratory readings within 3 days apart, taken at least 10 days following biliary stent placement; for patients with a biliary stent placed over 2 months ago, no obstruction or blockage can have occurred within the last 2 months
  • Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
  • Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

  • Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those whose adverse event due to agents administered more than 4 weeks earlier have not resolved or stabilized; patients who have been administered ABT-888 as part of a single or combination, phase 0 or I study, should not necessarily be excluded from participating in this study solely because of receiving prior ABT-888
  • Patients may not be receiving any other investigational agents
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to ABT-888 or other agents used in study
  • Peripheral neuropathy of severity greater than grade 1
  • Inability to take oral medications on a continuous basis
  • Evidence of bleeding diathesis
  • Patients with central nervous system (CNS) metastases must be stable after therapy for CNS metastases (such as surgery, radiotherapy or stereotactic radiosurgery) for at least 3 months and must be off steroid treatment prior to study enrollment
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ABT-888; these potential risks may also apply to other agents used in this study
  • Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; however, HIV-positive patients without an acquired immune deficiency syndrome (AIDS)-defining diagnosis who are not receiving agents with the potential for pharmacokinetic (PK) interactions with ABT-888 may be eligible
  • Patients with both hepatic and renal dysfunction will also be excluded
  • Patients who received and progressed on the combination of carboplatin/paclitaxel will not be eligible
  • Active seizure or history of seizure disorder

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Treatment (veliparib, paclitaxel, carboplatin)

Patients receive veliparib* PO BID on days 1-7 and paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 3. Courses repeat every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.

NOTE: * All patients receive a single dose of veliparib PO on day -6 before course 1 (except patients with very severe renal dysfunction who receive veliparib on day -5 or -6 to coincide with a dialysis day).

Given IV

其他名称:
  • 芽生威
  • 卡宝
  • 卡铂六醇
  • 卡铂
  • 卡布辛
  • 卡波索尔
  • 卡博泰克
  • CBDCA
  • 迪普拉塔
  • 埃卡尔
  • JM-8
  • 内洛林
  • 新铂金
  • 副铂
  • 副铂 AQ
  • 对铂
  • 铂金瓦斯
  • 核糖体
  • JM8

Given IV

其他名称:
  • 紫杉醇
  • 安扎塔克斯
  • Asotax
  • 布里他索
  • 普拉塞尔
  • 紫杉醇音乐会

Correlative studies

Given PO

其他名称:
  • ABT-888
  • PARP-1抑制剂ABT-888
  • ABT 888
  • ABT888

Correlative studies

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Veliparib 联合卡铂和紫杉醇的 MTD,根据使用国家癌症研究所不良事件通用术语标准 (NCI CTCAE) 版本 (v) 4.0 分级的 DLT 发生率确定
大体时间:21天
21天
PK parameters of veliparib
大体时间:Day -6 and 3 of course 1 after veliparib dosing

Standard quantitative and graphical statistical summaries of the derived PK parameters (e.g. area under curve and clearance) will be produced for each organ function cohort. The effect of dysfunction on pharmacokinetics will be explored by comparing each pharmacokinetic parameter across all cohorts using one-way analysis (analysis of variance) or Kruskal-Wallis test. The level of each protein will be compared between responders and non-responders using the Wilcoxon signed rank test.

Day -6 and 3 of course 1 after veliparib dosing

次要结果测量

结果测量
措施说明
大体时间
Incidence of toxicities as assessed by NCI CTCAE v4.0
大体时间:Up to 4 weeks after completion of study treatment

The maximum grade of toxicity for each category of interest will be recorded for each patient and the summary results will be tabulated by category, grade and dose level. Severe and life-threatening toxicities and adverse event-related deaths (>= grade 3) will be described on a patient-by-patient basis and will include any relevant baseline data.

Up to 4 weeks after completion of study treatment
Response rate as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
大体时间:Up to 4 weeks after completion of study treatment

Responses will be tabulated by disease diagnosis and by dose level. 95% confidence limits will also be reported on the response rates.

Up to 4 weeks after completion of study treatment
Incidence of stable disease as assessed by RECIST version 1.1
大体时间:Up to 4 weeks after completion of study treatment

Incidence of stable disease will be tabulated by disease diagnosis and by dose level.

Up to 4 weeks after completion of study treatment
Time to progression
大体时间:Up to 4 weeks after completion of study treatment

Displayed for all patients and for patients who have responded; no formal statistical analysis is planned.

Up to 4 weeks after completion of study treatment

其他结果措施

结果测量
措施说明
大体时间
Change in PAR levels
大体时间:Baseline to up to 4 weeks

Descriptive statistics (mean, standard deviation, median, range) for measurements of PAR levels will provided with 95% confidence intervals (CIs). When sample size permits, a formal statistical test using the Wilcoxon signed rank test will be used to compare the post treatment PAR levels to the baseline levels. When feasible, the level will be compared between responders and non-responders using the Wilcoxon signed rank test.

Baseline to up to 4 weeks
Change in gamma-H2AX levels
大体时间:Baseline to up to 4 weeks

Descriptive statistics (mean, standard deviation, median, range) for measurements of gamma-H2AX levels will provided with 95% CIs. When sample size permits, a formal statistical test using the Wilcoxon signed rank test will be used to compare the post treatment PAR levels to the baseline levels. When feasible, the level will be compared between responders and non-responders using the Wilcoxon signed rank test.

Baseline to up to 4 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

合作者

调查人员

  • 首席研究员:Hussein A Tawbi、University of Pittsburgh Cancer Institute (UPCI)

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2011年6月20日

初级完成 (实际的)

2017年11月10日

研究完成 (估计的)

2027年3月3日

研究注册日期

首次提交

2011年6月2日

首先提交符合 QC 标准的

2011年6月2日

首次发布 (估计的)

2011年6月3日

研究记录更新

最后更新发布 (实际的)

2026年11月18日

上次提交的符合 QC 标准的更新

2026年11月17日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他研究编号

  • NCI-2011-02500
  • U01CA070095 (美国 NIH 拨款/合同)
  • UM1CA186691 (美国 NIH 拨款/合同)
  • UM1CA186716 (美国 NIH 拨款/合同)
  • U01CA099168 (美国 NIH 拨款/合同)
  • U01CA062502 (美国 NIH 拨款/合同)
  • U01CA062505 (美国 NIH 拨款/合同)
  • U01CA062490 (美国 NIH 拨款/合同)
  • U01CA069856 (美国 NIH 拨款/合同)
  • UM1CA186690 (美国 NIH 拨款/合同)
  • UM1CA186717 (美国 NIH 拨款/合同)
  • UM1CA186709 (美国 NIH 拨款/合同)
  • N01CM00100 (美国 NIH 拨款/合同)
  • P30CA047904 (美国 NIH 拨款/合同)
  • NCI-2011-02500 (注册表标识符:CTRP (Clinical Trial Reporting Program))
  • CDR0000700997
  • UPCI 10-115
  • UPCI-10-115
  • 8808 (其他标识符:CTEP)
  • 8808 (其他标识符:UPMC Hillman Cancer Center)

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.